Lanreotide

产品说明书

Print
Chemical Structure| 108736-35-2 同义名 : BIM 23014;Laromustine;Lanreotidum;ITM-014T;ITM-014;Dermopeptin;BM 23014;BIM 23014C;Angiopeptin
CAS号 : 108736-35-2
货号 : A218062
分子式 : C54H69N11O10S2
纯度 : 99% HPLC
分子量 : 1096.323
MDL号 : MFCD03424071
存储条件：

Pure form Keep in dark place,Sealed in dry,Store in freezer, under -20°C

In solvent -20°C:3-6个月-80°C:12个月
溶解度 : -
动物实验配方：
生物活性
描述 Lanreotide (LAN), a synthetic cyclic octapeptide, is the analogue of somatostatin that can inhibit somatostatin receptor 2 (SSTR-2). Because its half-life is longer than somatostatin, lanreotide can be used clinically to treat neuroendocrine tumors that secrete excessive amounts of growth hormone (acromegaly) or other active hormones or neuropeptides[3]. Lanreotide treatment promoted a Th1 cytotoxic immune-phenotype in patients with NETs (neuroendocrine tumors) originated by intestinal sites[4]. Lanreotide was associated with significantly prolonged progression-free survival among patients with metastatic enteropancreatic neuroendocrine tumors of grade 1 or 2[5]. Lanreotide treatment for 3 months before trans-sphenoidal surgery effectively reduced tumour size, and improved surgical cure rate, in newly diagnosed patients with acromegaly resulting from invasive pituitary macroadenoma[6].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02668172 Acromegaly Phase 4 Unknown June 2017 Netherlands ... 展开 >> Erasmus Medical Center Rotterdam, South Holland, Netherlands, 3000CA 收起 <<
NCT01677910 Carcinoid Syndrome Phase 3 Completed - -
NCT00642720 Quality of Life ... 展开 >> Acromegaly 收起 << Phase 4 Completed - -
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

0.91mL

0.18mL

0.09mL

4.56mL

0.91mL

0.46mL

9.12mL

1.82mL

0.91mL
参考文献

[1]Michael M, Garcia-Carbonero R, et al. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review. Oncologist. 2017 Mar;22(3):272-285.

[2]Tong H, Wei B, et al. Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study. Oncotarget. 2017 Feb 24.

[3]LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Lanreotide. 2017 Apr 11

[4]Sciammarella C, Luce A, Riccardi F, Mocerino C, Modica R, Berretta M, Misso G, Cossu AM, Colao A, Vitale G, Necas A, Fedacko J, Galdiero M, Correale P, Faggiano A, Caraglia M, Capasso A, Grimaldi A. Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus. Front Oncol. 2020 Jul 7;10:1047

[5]Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014 Jul 17;371(3):224-33

[6]Li ZQ, Quan Z, Tian HL, Cheng M. Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma. J Int Med Res. 2012;40(2):517-24